Erste Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Erste Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-28,400	Closed	-$80.4K	–	645
2025 Q3	$80.4K	Hold	28,400	–	–	﹤0.01%	587
2025 Q2	$70.1K	Hold	28,400	–	–	﹤0.01%	842
2025 Q1	$67K	Hold	28,400	–	–	﹤0.01%	504
2024 Q4	$156K	Hold	28,400	–	–	﹤0.01%	494
2024 Q3	$239K	Hold	28,400	–	–	﹤0.01%	474
2024 Q2	$201K	Hold	28,400	–	–	﹤0.01%	478
2024 Q1	$244K	Hold	28,400	–	–	﹤0.01%	471
2023 Q4	$191K	Hold	28,400	–	–	﹤0.01%	482
2023 Q3	$273K	Hold	28,400	–	–	﹤0.01%	460
2023 Q2	$355K	Hold	28,400	–	–	0.01%	449
2023 Q1	$383K	Hold	28,400	–	–	0.01%	448
2022 Q4	$400K	Hold	28,400	–	–	0.01%	443
2022 Q3	$722K	Hold	28,400	–	–	0.02%	383
2022 Q2	$790K	Hold	28,400	–	–	0.02%	382
2022 Q1	$1.01M	Buy	+28,400	New	+$952K	0.02%	352

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Erste Asset Management's MRVI Position: Q4 2025 in Review

Erste Asset Management sold out of Maravai LifeSciences (MRVI) in Q4 2025, closing a stake of 28,400 shares — an estimated $80.4K sold.

Erste Asset Management first reported a position in MRVI in Q1 2022 and held it in 15 quarters. The position peaked at $1.01M in Q1 2022. 159 funds tracked by Wall St. Rank hold MRVI as of Q4 2025.

Erste Asset Management reported no remaining Maravai LifeSciences position as of Q4 2025 after selling out during the quarter.
Erste Asset Management sold 28,400 Maravai LifeSciences shares in Q4 2025, an estimated $80.4K.
Erste Asset Management first reported a position in Maravai LifeSciences in Q1 2022 and held it in 15 quarters.
Erste Asset Management's Maravai LifeSciences position peaked at $1.01M in Q1 2022.
159 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2025.

Based on Erste Asset Management's 13F filing for Q4 2025, filed 11 Feb 2026.